Following AstraZeneca's most recent rejection of Pfizer's bid, many may ask if this is a lost opportunity for British innovation, or the salvation of it? Neither, George Freeman says.
via CNN.com - Top Stories http://ift.tt/1owSdb5
via CNN.com - Top Stories http://ift.tt/1owSdb5
No comments:
Post a Comment